Wayfinder Biosciences
Targeting RNA with small molecules is a new modality with massive potential to unlock incurable diseases. But the rules remain unclear.
* Data source: Crunchbase
- Founded
- 2020
- Employees*
- 10
- Funding to Date*
- $6,800,000
- Website
- wayfinderbio.com
“Many key drivers of disease remain impossible or extremely challenging to drug today. By targeting at the RNA level, we can prevent disease-proteins from being made in the first place.”
It takes the world's RNA experts years to make an RNA-based biosensor. Wayfinder does it in 2 weeks.
Wayfinder has built a drug discovery platform for small molecules that modulate RNA targets. Their technology generates highly quantitative data on RNA-small molecules interactions at high-throughput. Combined with their AI/ML virtual screening models, they can search billions of molecules for RNA modulators in just 3 days.
And they do it way faster than anyone else in the world. Wayfinder is WAY faster.
A spinout from the Center for Synthetic Biology at the University of Washington, Wayfinder has internal programs in oncology and unique technologies to unlock RNA drugging.
